Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

New Jersey Innovation Institute (NJII)

Newark Introduces City-wide Initiative to Create a ‘Smart City,’ Better Connecting Resident to Each Other and the World

connected-worldNewark, NJ, October, 29, 2016 — Newark officials on October 17 joined with the New Jersey Institute of Technology (NJIT), the New Jersey Innovation Institute (NJII) an NJIT corporation that applies the intellectual and technological resources of the state’s science and technology university, and corporate partners to announce a long-term program that would help propel the city into becoming one of the most technologically-connected cities in the nation.

Newark is taking the necessary steps toward becoming a “Smart City,” as part of a sweeping White House initiative that brings together academia, government and business to innovate and create the next generation of urban technology and infrastructure. Continue reading

NJII Wins $49.6 Million Federal Grant to Improve Clinical Care Practices in NJ

Newark, NJ, October 8, 2015 ― Backed by a nearly $50 million grant from the U.S. Department of Health and Human Services, the New Jersey Innovation Institute (NJII) will spend the next four years working with thousands of medical practices in the state to improve the quality and efficiency of the care they provide, while also lowering its cost.

Through its Transforming Clinical Practice Initiative (TCPI), the federal government seeks to move practices from a fee-for-service model that reimburses caregivers for dispensing treatment at episodic visits to what is known as a “value-based” care system that compensates them for keeping their patients well through ongoing, evidence-based disease management. Continue reading